

681635 Box SEQ
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elazar Rabbani et al
Serial No. 08/978,632
Filed: November 25, 1997
Title: **NOVEL PROPERTY EFFECTING
AND/OR PROPERTY EXHIBITING
COMPOSITIONS FOR THERAPEUTIC
AND DIAGNOSTIC USE**

U.S. PATENT & TRADEMARK OFFICE
AUG 06 1999
JC48

WD
RECEIVED
AUG 10 1999
TECH CENTER 1600/2500
Group Art Unit: 1635

Examiner: Mary M. Schmidt
#11/D
9-1-99

527 Madison Avenue, 9th Floor
New York, New York 10022
August 3, 1999

FILED BY FIRST CLASS MAIL

Honorable Commissioner
of Patents and Trademarks
Washington, D.C. 20231

Attention: **Box Sequence**

**SECOND COMMUNICATION DIRECTED TO NOTICE
TO COMPLY WITH SEQUENCE RULES**


Dear Sirs:

This Second Communication follows Applicants' October 26, 1998 Communication directed to the Notice To Comply With Sequence Rules that was attached to the Notice to File Missing Parts of Application – Filing Date Granted dated April 24, 1998 (which applicants did not originally receive, and which was remailed on June 1, 1998) in connection with the above-identified application.

Applicants hereby submit the following documents or items:

1. a substitute initial paper copy of the substitute Sequence Listing;
2. a Second Amendment directing entry of the substitute Sequence Listing into the specification;
3. a computer readable form (CFR) copy of the substitute Sequence Listing; and

ENZ-53(C)

FIRST CLASS CERTIFICATE	
I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner of Patents & Trademarks Washington, D.C. 20231	
 Ronald C. Fedus Reg. No. 32567	AUG 3 99 Date

4. X The Commissioner is hereby authorized to charge payment of the filing fee as well as the following fees associated with this application or to credit any overpayment to Deposit Account No. 05-1135. A duplicate copy of this sheet is enclosed.
- X Any additional filing fees required under 37 CFR §1.16.
- X Any patent application processing fees under 37 CFR §1.17.
5. X The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 05-1135. A duplicate copy of this sheet is enclosed.
- X Any patent application processing fees under 37 CFR §1.17.
- The issue fee set in 37 CFR §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR §1.311(b).
- Any filing fees under 37 CFR §1.16 for presentation of extra claims.
6. A check in the amount of \$ is enclosed.
7. Cancel claims .
8. X Amend the specification by inserting before the first line of the sentence: — This is a X continuation, divisional, continuation-in-part, of application Serial No. 08/978,632, filed on November 25, 1997. —
9. Transfer the drawings from the prior application.
10. Informal Formal drawings are enclosed.
11. Abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.
12. Priority of application Serial No. filed on is claimed under 35 U.S.C. §119.
The certified copy of the priority application has been filed in prior application Serial No. , filed .
13. The prior application is assigned of record to Enzo Therapeutics, Inc., c/o Enzo Biochem, Inc., 527 Madison Avenue, New York, New York 10022. [A copy of the originally submitted Assignment and the Notice of Recordation are enclosed herewith.]
14. A preliminary amendment is enclosed.

Elazar Rabbani et al.

Serial No.: Not Yet Assigned

Filed: Herewith

Page: 3 (Request for a Continuation Application Under 37 C.F.R. §1.62 -
May 8, 2000)


15. X The power of attorney in the prior application is to:
Ronald C. Fedus, Reg. No. 32,567.
- (a) X The power appears in the original papers in the prior application.
- (b) Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- (c) A copy of a new substitute power of attorney is enclosed.
- (d) X Address all future communications to: (May only be completed by applicant, or attorney or agent of record.)

Ronald C. Fedus, Esq.
Enzo Therapeutics, Inc.
c/o Enzo Biochem, Inc.
527 Madison Avenue (9th Floor)
New York, New York 10022

16. I hereby verify that the attached papers are a true copy of prior application Serial No. .

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

May 8, 2000
Date



Ronald C. Fedus
Registration No. 32, 567
Attorney for Applicants
 Inventor(s)
 Assignee of Complete Interest
 X Attorney or Agent of Record
 Filed under 37 CFR §1.34(a)

Address of Signator:
Enzo Therapeutics, Inc.
c/o Enzo Biochem, Inc.
527 Madison Avenue (9th Floor)
New York, New York 10022

lctword\usprosecution\enz53\CFWC.050800

Attorney's Docket No. Enz-53(C)(FWC)